Home » Stocks » OPK

OPKO Health, Inc. (OPK)

Stock Price: $4.14 USD -0.19 (-4.28%)
Updated Mar 4, 2021 2:06 PM EST - Market open
Market Cap 3.10B
Revenue (ttm) 1.44B
Net Income (ttm) 30.59M
Shares Out 640.66M
EPS (ttm) 0.05
PE Ratio 86.15
Forward PE 30.03
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $4.14
Previous Close $4.32
Change ($) -0.19
Change (%) -4.28%
Day's Open 4.30
Day's Range 4.08 - 4.53
Day's Volume 9,781,281
52-Week Range 1.12 - 6.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 3 days ago

These seven penny stocks are most likely to push through the $5 mark having built a significant head of steam in the past year. The post 7 Penny Stocks Close To Busting Through the $5 Mark app...

Other stocks mentioned: LIVX, LLNW, NOK, OGI, WTRH
Benzinga - 4 days ago

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases th...

Other stocks mentioned: ADC, CAR, ZTS, AAT, INCY, MTEM, RPRX, SONO, USLM
Business Wire - 6 days ago

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Au...

Other stocks mentioned: PFE
InvestorPlace - 1 week ago

With the crazy bullishness in the market, you can't find too many discounted plays. However, these sleeper stocks might just give your portfolio the kickstart it needs in 2021.

Other stocks mentioned: AHEXY, AMRN, EATBF, KELYA, LLNW, SKX, SWCH
PRNewsWire - 1 week ago

NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced its participation in the NY Forward Rapid Testing Program and opened eig...

Zacks Investment Research - 1 week ago

OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.

Benzinga - 1 week ago

Opko Health Inc (NASDAQ: OPK) reported Q4 results that came in above expectations with EPS of $0.05 beating the estimate of $0.04 and sales of $494.6 million higher than the consensus of $443....

The Motley Fool - 1 week ago

Hint: Investors are more focused on concerns about the future than successes of the recent past.

Zacks Investment Research - 1 week ago

OPKO Health (OPK) delivered earnings and revenue surprises of 25.00% and 13.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 1 week ago

Shares of OPKO Health (NASDAQ:OPK) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 266.67% over the past year to $0.05, which beat...

Zacks Investment Research - 2 weeks ago

OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.

GlobeNewsWire - 1 month ago

MIAMI, Feb. 03, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2020, as well as discuss financ...

Benzinga - 1 month ago

The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causin...

Other stocks mentioned: CLVS, DVAX, LCI, NAKD, PGEN, SENS, TXMD, UMC, VBIV
InvestorPlace - 1 month ago

Penny stocks are cheap for a reason, as there are obvious flaws. However, with those flows comes opportunity.

Other stocks mentioned: CAIXY, CLVS, DHT, MBIO, RNWK, RYCEY
Zacks Investment Research - 1 month ago

OPKO Health's (OPK) BioReference introduces an in-home, fully-integrated digital platform providing access to diagnostic services.

Seeking Alpha - 1 month ago

OPKO Health, Inc. (OPK) CEO Phil Frost Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

PRNewsWire - 1 month ago

ELMWOOD PARK, N.J., Jan. 13, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today introduced Scarlet Health™, an in-home, fully integrated digital p...

GlobeNewsWire - 1 month ago

Calls on Analysts and Stockholders Attending J.P. Morgan's Healthcare Conference to Determine Whether Management Disputes our Analysis and Stands by Original 4Q'20 Guidance Calls on Analysts a...

Zacks Investment Research - 1 month ago

OPKO Health (OPK) closed the most recent trading day at $4.48, moving +1.82% from the previous trading session.

The Motley Fool - 1 month ago

It's the perfect time for a wealthy CEO to ride off into the sunset.

GlobeNewsWire - 1 month ago

MIAMI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 39th Annual J.P. Morgan Healthcare Conference being held v...

Zacks Investment Research - 2 months ago

OPKO Health's (OPK) BioReference commences mandatory, large-scale COVID-19 testing programs for fans for AFC Division Wild Card playoff game.

PRNewsWire - 2 months ago

ELMWOOD PARK, N.J., Jan. 4, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR tests for public s...

Business Wire - 2 months ago

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the US Food and Drug Administration (FDA) has accepted for filing the initial...

Other stocks mentioned: PFE
Seeking Alpha - 2 months ago

OPKO Health has been experiencing an historic year in terms of business achievements, execution, and public recognition. The current Opko share price has been trading at extremely depressed le...

The Motley Fool - 2 months ago

These interesting low-cost stocks have the opportunity to grow.

Other stocks mentioned: ATRS, FLNT
GlobeNewsWire - 2 months ago

MIAMI, Dec. 21, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Roger Medel, M.D. as an independent member of its Board of Directors, effective Dece...

Benzinga - 2 months ago

Having college and professional athletes play sports during a pandemic can create logistics problems with social distancing and COVID-19 testing. Two small cap companies have won contracts to ...

Other stocks mentioned: PAE
The Motley Fool - 3 months ago

Rumors of a potential sale of the company's growth hormone royalty stream excited investors.

Seeking Alpha - 3 months ago

OPKO Health, Inc. (OPK) Management Presents at Jefferies 2020 Virtual London Healthcare Conference (Transcript)

Benzinga - 3 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...

Other stocks mentioned: IBM, KHC, HBI, TUP, VRTX, PI
GlobeNewsWire - 3 months ago

MIAMI, Nov. 11, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in three upcoming virtual investor conferences.

The Motley Fool - 3 months ago

Patient investors could double their money in these two stocks that the market has temporarily cast aside.

Other stocks mentioned: BMRN
Zacks Investment Research - 4 months ago

OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.

The Motley Fool - 4 months ago

The healthcare company reported Q3 results that some didn't think were strong enough.

Seeking Alpha - 4 months ago

OPKO Health, Inc. (OPK) CEO Phil Frost on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

OPKO Health (OPK) delivered earnings and revenue surprises of 0.00% and 14.07%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 months ago

Shares of OPKO Health (NASDAQ:OPK) fell 6.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 144.44% year over year to $0.04, which ...

Zacks Investment Research - 4 months ago

OPKO Health's (OPK) third-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.

Zacks Investment Research - 4 months ago

In the latest trading session, OPKO Health (OPK) closed at $4.30, marking a +0.7% move from the previous day.

Zacks Investment Research - 4 months ago

OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.

Zacks Investment Research - 4 months ago

OPKO Health (OPK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 4 months ago

Despite high-profile agreements to provide coronavirus testing, this small-cap company might not pass the test in the long term.

The Motley Fool - 4 months ago

One is producing large numbers of COVID-19 diagnostic tests; the other may be among the first companies to get a coronavirus vaccine approved.

Other stocks mentioned: BNTX
The Motley Fool - 4 months ago

Successful partnerships with major sports leagues and updated guidance may mean coronavirus testing is here to stay.

Other stocks mentioned: QDEL
Seeking Alpha - 4 months ago

Pounding The Table For Undervalued OPKO Health

GlobeNewsWire - 4 months ago

MIAMI, Oct. 13, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2020, as well as discuss finan...

PRNewsWire - 4 months ago

ELMWOOD PARK, N.J., Oct. 9, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ :OPK), today announced the beginning of its COVID-19 testing program for New Yo...

PRNewsWire - 4 months ago

SEATTLE, Oct. 8, 2020 /PRNewswire/ -- UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA Case No. 1:18-cv-23786-MARTINEZ-OTAZO-REYES CHARLES STEINBERG, individually and on Behalf of All...

Business Wire - 4 months ago

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study eva...

Other stocks mentioned: PFE

About OPK

OPKO Health, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and go... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 2, 1995
CEO
Phillip Frost
Employees
5,269
Stock Exchange
NASDAQ
Ticker Symbol
OPK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for OPKO Health stock is "Buy." The 12-month stock price forecast is 8.25, which is an increase of 99.52% from the latest price.

Price Target
$8.25
(99.52% upside)
Analyst Consensus: Buy